MPLT
MapLight Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.65 / 10
Netural
Analyst coverage is overwhelmingly bullish (Strong Buy/Buy across four institutions), and fund-flow analysis is excellent with consistent inflows across all size brackets. This combination typically supports price appreciation, especially in a biotech sector where sentiment can drive share prices.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-21
InstitutionJefferies
Times predicted1
Historical Win Rate100.0%
What is the market sentiment for MPLT?
- MPLT holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.65/10 (Netural).
